CD55/DAF Antibody (BRIC216) - BSA Free

• Reactivity: Hu
• Applications: WB, Flow, Func, IP
• Clone: BRIC216
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1.0 mg/ml

CD55/DAF Antibody (BRIC216) - BSA Free Summary

• Description: Novus Biologicals Mouse CD55/DAF Antibody (BRIC216) - BSA Free (NB100-65914) is a monoclonal antibody validated for use in WB, Flow and IP. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: Human fibroblast cell line
• Specificity: NB100-65914 recognizes the CD55 antigen. BRIC 216 recognizes the consensus region 3 of the DAF molecule, which contains the functional site, and the antibody blocks the function of DAF.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: CD55
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 1:10 - 1:1000
  • Functional
  • Immunoprecipitation 1:10 - 1:500
  • Western Blot 1:100 - 1:2000
• Application Notes: The antigen is pronase and trypsin resistant and chymotrypsin sensitive. This antibody has a functional binding affinity to erythrocytes of 8.7 x 10^7 M^-1. This product contains sodium azide, removal by dialysis is recommended prior to use in functional assays. For Flow Cytometry: Use 10 ul of the suggested working dilution to label 10^6 cells in 100 ul.
• Control:

  CD55/DAF Overexpression Lysate

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: TRIS buffered saline, <100mM glycine
• Preservative: <0.1% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Protein G purified

Alternate Names for CD55/DAF Antibody (BRIC216) - BSA Free

• CD55 antigen
• CD55 molecule, decay accelerating factor for complement (Cromer blood group)
• CD55
• CR
• CRdecay accelerating factor for complement (CD55, Cromer blood group system)
• CROMDAFcomplement decay-accelerating factor
• DAF
• decay accelerating factor for complement
• TC

Background

Avoidance by host tissues of attack by autologous complement proteins is dependent in part on the activities of membrane regulatory factors. One molecule involved in this control is a 70 kD glycoprotein termed decay accelerating factor (DAF), or CD55. Interruption by CD55 of the complement sequence at an early step in activation effectively halts progression of the cascade and prevents consequent cell injury. In man, CD55 is expressed on the plasma membrane of all cell types that are in intimate contact with plasma complement proteins. This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade. CD55 also acts as the receptor for echovirus 7 and related viruses(echoviruses 13, 21, 29 and 33). It is attached to the membrane by a GPI-anchor.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: CD55
• Entrez:
  • 1604(Human)
• Uniprot:
  • P08174()
  • P08174()